pirenzepine has been researched along with Parkinson Disease in 33 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine." | 5.30 | Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. ( Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E, 1999) |
| "To compare olanzapine and clozapine for safety and efficacy measures of psychosis and motor function in patients with PD and chronic hallucinations." | 5.09 | Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. ( Blasucci, LM; Goetz, CG; Leurgans, S; Pappert, EJ, 2000) |
| "In schizophrenia and Parkinson's disease, cortical and subcortical motor organization is influenced by primary disease conditions and neuroleptic treatment." | 2.71 | Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study. ( Deuticke, C; Hajak, G; Müller, JL; Putzhammer, A; Röder, CH; Winkler, J, 2003) |
| "Olanzapine is a novel atypical antipsychotic drug with few reported extrapyramidal side effects which may be more suitable for controlling hallucinosis in these patients." | 2.69 | Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. ( Ford, KS; Graham, JM; Sagar, HJ; Sussman, JD, 1998) |
| "Pretreatment with pirenzepine (100 mg p." | 2.69 | Muscarinic cholinergic mediation of the GH response to gamma-hydroxybutyric acid: neuroendocrine evidence in normal and parkinsonian subjects. ( Caffarra, P; Chiodera, P; Coiro, V; Malvezzi, L; Saginario, A; Scaglioni, A; Volpi, R, 2000) |
| "The psychotic symptoms associated with Parkinson's disease can be as varied as the motor symptoms." | 2.40 | Management of psychotic aspects of Parkinson's disease. ( Juncos, JL, 1999) |
| "Four patients affected by severe Parkinson's disease developed leucopenia (900-1200 WBC) during treatment of psychosis (3) or untreatable insomnia (1) with clozapine (37." | 1.31 | Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine. ( Bonanni, L; Gambi, F; Iacono, D; Onofrj, M; Thomas, A, 2000) |
| "Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine." | 1.30 | Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. ( Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 11 (33.33) | 18.2507 |
| 2000's | 18 (54.55) | 29.6817 |
| 2010's | 2 (6.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, LM | 1 |
| Sheffler, D | 1 |
| Williams, R | 1 |
| Bridges, TM | 1 |
| Kennedy, JP | 1 |
| Brogan, JT | 1 |
| Mulder, MJ | 1 |
| Williams, L | 1 |
| Nalywajko, NT | 1 |
| Niswender, CM | 1 |
| Weaver, CD | 1 |
| Conn, PJ | 2 |
| Lindsley, CW | 2 |
| Miller, NR | 1 |
| Daniels, RN | 1 |
| Lee, D | 1 |
| Wang, Q | 1 |
| Wei, X | 1 |
| Gao, H | 1 |
| Li, J | 1 |
| Liao, J | 1 |
| Liu, X | 1 |
| Qin, B | 1 |
| Yu, Y | 1 |
| Deng, C | 1 |
| Tang, B | 1 |
| Huang, XF | 1 |
| Friedman, JH | 2 |
| Fernandez, HH | 2 |
| Breier, A | 1 |
| Sutton, VK | 1 |
| Feldman, PD | 1 |
| Kadam, DL | 1 |
| Ferchland, I | 1 |
| Wright, P | 1 |
| Ondo, WG | 1 |
| Levy, JK | 1 |
| Vuong, KD | 1 |
| Hunter, C | 1 |
| Jankovic, J | 1 |
| Piggott, MA | 1 |
| Owens, J | 1 |
| O'Brien, J | 1 |
| Colloby, S | 1 |
| Fenwick, J | 1 |
| Wyper, D | 1 |
| Jaros, E | 1 |
| Johnson, M | 2 |
| Perry, RH | 2 |
| Perry, EK | 2 |
| Müller, JL | 1 |
| Deuticke, C | 1 |
| Putzhammer, A | 1 |
| Röder, CH | 1 |
| Hajak, G | 1 |
| Winkler, J | 1 |
| Hoeh, N | 1 |
| Gyulai, L | 1 |
| Weintraub, D | 1 |
| Streim, J | 1 |
| Joyce, JN | 1 |
| Wolters, EC | 1 |
| Jansen, EN | 1 |
| Tuynman-Qua, HG | 1 |
| Bergmans, PL | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Tallón-Barranco, A | 1 |
| Ortí-Pareja, M | 1 |
| Zurdo, M | 1 |
| Porta, J | 1 |
| Molina, JA | 1 |
| Friedman, J | 1 |
| Graham, JM | 1 |
| Sussman, JD | 1 |
| Ford, KS | 1 |
| Sagar, HJ | 1 |
| Juncos, JL | 1 |
| Walker, Z | 1 |
| Grace, J | 1 |
| Overshot, R | 1 |
| Satarasinghe, S | 1 |
| Swan, A | 1 |
| Katona, CL | 1 |
| McKeith, IG | 1 |
| Aarsland, D | 1 |
| Larsen, JP | 1 |
| Lim, NG | 1 |
| Tandberg, E | 1 |
| Rudolf, J | 1 |
| Ghaemi, M | 1 |
| Schmülling, S | 1 |
| Molho, ES | 1 |
| Factor, SA | 1 |
| Volpi, R | 1 |
| Chiodera, P | 1 |
| Caffarra, P | 1 |
| Scaglioni, A | 1 |
| Malvezzi, L | 1 |
| Saginario, A | 1 |
| Coiro, V | 1 |
| Weiner, WJ | 1 |
| Minagar, A | 1 |
| Shulman, LM | 1 |
| Granger, AS | 1 |
| Hanger, HC | 1 |
| Goetz, CG | 1 |
| Blasucci, LM | 1 |
| Leurgans, S | 1 |
| Pappert, EJ | 1 |
| Onofrj, M | 2 |
| Thomas, A | 2 |
| Shad, MU | 1 |
| Marsh, C | 1 |
| Preskorn, SH | 1 |
| Bonanni, L | 1 |
| Iacono, D | 1 |
| Gambi, F | 1 |
| Sa, DS | 2 |
| Lang, AE | 2 |
| Leucht, S | 1 |
| Chacón, JR | 1 |
| Durán, E | 1 |
| Durán, JA | 1 |
| Alvarez, M | 1 |
| Nishino, N | 1 |
| Fujiwara, H | 1 |
| Noguchi-Kuno, SA | 1 |
| Tanaka, C | 1 |
| Smith, CJ | 1 |
| Candy, JM | 1 |
| Bonham, JR | 1 |
| Dick, DJ | 1 |
| Fairbairn, A | 1 |
| Blessed, G | 1 |
| Birdsall, NJ | 1 |
3 reviews available for pirenzepine and Parkinson Disease
| Article | Year |
|---|---|
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Pharmacologic management of psychosis in the elderly: a critical review.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm | 2003 |
Management of psychotic aspects of Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; C | 1999 |
7 trials available for pirenzepine and Parkinson Disease
| Article | Year |
|---|---|
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dopamine Agents; Female; Humans; Male; Olanzapine; Park | 2002 |
Olanzapine treatment for dopaminergic-induced hallucinations.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dopamine Agonists; Double-Blind Me | 2002 |
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Dopamine; Female; Fingers; Functional | 2003 |
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Response Relationship, Dru | 1998 |
Muscarinic cholinergic mediation of the GH response to gamma-hydroxybutyric acid: neuroendocrine evidence in normal and parkinsonian subjects.
Topics: Aged; Area Under Curve; Human Growth Hormone; Humans; Male; Middle Aged; Muscarinic Antagonists; Neu | 2000 |
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.
Topics: Aged; Behavior; Benzodiazepines; Clozapine; Double-Blind Method; Female; Hallucinations; Humans; Mal | 2000 |
[Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Female; Humans | 2002 |
23 other studies available for pirenzepine and Parkinson Disease
| Article | Year |
|---|---|
Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists.
Topics: Combinatorial Chemistry Techniques; Dose-Response Relationship, Drug; Dystonia; Heterocyclic Compoun | 2008 |
Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists.
Topics: Amino Acid Sequence; Animals; Benzamides; CHO Cells; Cricetinae; Cricetulus; Dystonia; Humans; Mice; | 2010 |
Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory.
Topics: Animals; Brain; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2014 |
Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Autoradiography; Basal Ganglia; Cerebral Cortex; Female; Gyrus Cinguli; Hum | 2003 |
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases.
Topics: Aged; Aged, 80 and over; Autoradiography; Benzazepines; Dopamine; Female; Humans; Male; Mazindol; Mi | 1993 |
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Parkinso | 1996 |
Olanzapine can worsen parkinsonism.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Parkinson Disease; Pi | 1998 |
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dopamine Agonists; Female; Humans; M | 1998 |
Olanzapine in dementia with Lewy bodies: a clinical study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Contraindicatio | 1999 |
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Dose-Response Relationship, Drug; Female; Hum | 1999 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine | 1999 |
Worsening of motor features of parkinsonism with olanzapine.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Female; Humans | 1999 |
Quetiapine for l-dopa-induced psychosis in PD.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Levodopa | 2000 |
Olanzapine: extrapyramidal side effects in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Extrapyramidal Tracts; Female; Hallu | 1999 |
Quetiapine for l-dopa-induced psychosis in PD.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Levodopa; Parkinson Disease; Pirenzepine; Psychose | 2000 |
One further case of pancytopenia induced by olanzapine in a Parkinson's disease patient.
Topics: Aged; Benzodiazepines; Humans; Male; Olanzapine; Pancytopenia; Parkinson Disease; Pirenzepine | 2001 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Halo | 2001 |
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationshi | 2000 |
Olanzapine for psychosis in Parkinson's disease.
Topics: Benzodiazepines; Hallucinations; Humans; Olanzapine; Parkinson Disease; Pirenzepine | 2001 |
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Hallucinations; Hu | 2001 |
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.
Topics: Antipsychotic Agents; Benzodiazepines; Bias; Clozapine; Hallucinations; Humans; Olanzapine; Parkinso | 2001 |
GABAA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson's disease.
Topics: Aged; Brain; Choline O-Acetyltransferase; Dopamine; Female; Glutamate Decarboxylase; Humans; Male; M | 1988 |
Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders.
Topics: Acetylcholinesterase; Aging; Choline O-Acetyltransferase; Cognition Disorders; Hippocampus; Humans; | 1988 |